Looking at long-term OPV use and at fractional IPV dosage

Looking at long-term OPV use and at fractional IPV dosage

The New England Journal of Medicine has published today two studies on polio eradication, offering useful new insights both for the pre- and post-eradication era.

In the first study, Helen Jenkins from Imperial College London et al, examined the implications of the circulating vaccine-derived poliovirus (cVDPV) in Nigeria. The study reaffirms that cVDPVs can regain transmissibility and pathogenicity that is similar to that of wild polioviruses. For the pre-eradication era, this supports the 2007 recommendation of the Advisory Committee on Poliomyelitis Eradication that cVDPVs be responded to in the same manner as wild poliovirus outbreaks. For the post-eradication era, this study reinforces the importance of solid planning for the management of long-term poliovirus risks – especially cVDPVs – in particular the eventual cessation of oral polio vaccine use in routine immunization programmes.

The second study, by Dr Ali Jafer Mohammed from the Ministry of Health in Oman, et al, presents the results of a clinical trial on fractional doses of inactivated polio vaccine (IPV) in Oman. The trial compared seroconversion rates with fractional IPV doses (1/5th of a full dose) to whole dose IPV in infants to evaluate this potential strategy for making the vaccine more affordable for use in low- and low-middle income countries if needed. The data found that in that setting, fractional doses of IPV administered intradermally at 2, 4 and 6 months, as compared with full doses of IPV given intramuscularly in the same schedule, achieve similar seroconversion rates, though with lower antibody titers. Together with our partners, the Global Polio Eradication Initiative is pursuing its work on evaluating a variety of approaches to achieve affordable IPV options for the post-OPV era.

The need to effectively manage cVDPVs both in the pre- and post-eradication eras, and the importance of pursuing strategies to reduce the cost of IPV for the post-eradication era, were underscored in the accompanying editorial ‘The bumpy road to polio eradication’, by Dr John F Modlin.

Related


Related News

   16/02/2018
Polio can’t be cured, but it can be prevented. Two important tools help to prevent polio – two safe, effective vaccines. Find out about the oral polio vaccine and the inactivated poliovirus vaccine and their roles in the polio eradication effort.
   16/02/2018
In Afghanistan, frontline health workers explain to parents why the polio vaccine must be delivered multiple times
   15/02/2018
Update on polio eradication efforts in Afghanistan for January 2018
   12/02/2018
The polio surveillance system is finding the virus in the most challenging areas so that children can be protected and polio stopped for good.
   09/02/2018
Sudan is on guard against polio, despite no case in eight years
   02/02/2018
Mohammed Mohammedi, country support officer for the Eastern Mediterranean region, speaks to us about the main challenges facing countries and communities which are at risk of re-infection.